Drug utilization review and quality of life of biosimilars used in oncology in tertiary care hospital
Journal Title: International Journal of Research in Pharmacology & Pharmacotherapeutics (IJRPP) - Year 2019, Vol 8, Issue 3
Abstract
Background Biosimilars are considered to be one of the solutions to combat the substantially increasing costs of cancer treatment and its imminent introduction is expected to expand affordability worldwide. Biosimilars were developed as copies of original products that were themselves copies/better biosimilars of natural proteins. Objectives To review the drug utilization and Quality of life of biosimilars used in oncology patients. Methods It was a Hospital based observational, prospective study conducted by random selection of 50 patients. The data was collected regarding demographic details of the patient, chemotherapeutic drugs and administration,diagnosis, laboratory tests, mammography, PET (positron emission tomography), present complaints, history of patients and QOL of patients were also recorded. Patients were included in the study after obtaining verbal informed consent. Results and discussion In this prospective observational study the drug utilization review of biosimilars in various types of cancers were evaluated in a total of 50 patients.Among 50 patients who were treated with biosimilars and chemotherapeutics, 22% were male and 78% were female. The mean total scores for breast cancer, lung cancer, melanoma,NHL ,HL Urothelial carcinoma and colon cancer subjects at final visit increased compared to initial visit. This increment was highly significant statistically and the values were found to be [t= 30.9487, p= 0.0001] at 95% confidence interval. Conclusion All biosimilars showed improvement in symptoms &QOL scores. During the study period it was revealed that the most commonly used biosimilars for breast cancer was Trastuzumab, lung cancer durvalumab, melanoma & hodgkin’s lymphoma & urothelial carcinoma & colon cancer nivolumab, non-hodgkin’s lymphoma rituximab. The maximum improvement in QOL was obtained with nivolumab in urothelial cancer, melanoma &Hodgkin’s lymphoma patients.
Authors and Affiliations
Dr. Syeda Zaineb Kubra Hussaini
Keywords
Related Articles
- EP ID EP655359
- DOI -
- Views 51
- Downloads 0
Find out the prevalance of various non-variceal diseases producing upper GI bleeding
Non variceal upper G.I bleeding is the bleeding from a source proximal to the ligament of teres. Advances in medical technology particulars the increased availability and application or diagnostic and the operatic endos...
Prescribing pattern of drugs in SNCU at a tertiary care hospital in South India
BACKGROUND SNCU (Sick New Born Care Unit) is meant to reduce the case fatality among sick newborns, either born within the hospital or outside including home delivery. The study of prescribing pattern is a part of the m...
Epidemiology and Management of Panfacial Fractures and the Associated Injuries in Andhra Pradesh
Background Facial Trauma is considered as one of the leading causes of death among people who are aged under 40 years. Patients with facial fractures may be associated with a variety of injuries of other regions of the b...
Changes in morphological, biochemical and yield Parameters of Macrotyloma uniflorum (L.) due to Panchagavya spray
A field experiment was conducted to find the variation in growth, biochemical and yield parameters of Horse gram under different concentrations (control, 1, 3, 5, 7.5 and 10%) of panchagavya, and all the parameters were...
A review on causes of diabetes and foot ulcer
Current review was regarding Diabetes mellitus along with its causes for foot ulcer. Many studies were conducted regarding etiology of diabetes mellitus. This review highlights the prevalence of diabetes and its neurop...